��������

Born in Germany in 1966, Marc Voigt is a business executive with over two decades of experience in the medical and financial industries. After earning their degree in Business Administration from the University of Cologne, Voigt began their career as an investment manager for Deutsche Life Science. Marc then moved to NET.IPO AKTIENGESELLSCHAFT, where they served as business development manager before joining Allianz as deputy manager.

In 2004, Voigt transitioned to the biotech industry, taking on executive positions at Medical Enzymes AG and Revotar Biopharmaceuticals AG. Marc served as CFO and CBO for both companies before leaving Revotar in 2010 to become CEO of Immutep. Under Voigt's leadership, Immutep has become a leading player in the immunotherapy space, with several groundbreaking treatments currently in development.

Some direct reports include Deanne Miller - COO, General Counsel & Company Secretary, Christian Mueller - VP, Strategic Development, and James Flinn - Intellectual Property & Innovation Director.